Anti-VEGF agents: indications and current options

Written by: Mr Hadi Zambarakji
Published:
Edited by: Aoife Maguire

Anti-VEGF agents are used in order to treat a number of eye conditions. Highly regarded consultant opthalmologist Mr Hadi Zambarakji explains everything you need to know about these agents, including the differences between each anti-VEGF agent, how they are injected and associated complications.

 

What is Vascular Endothelial Growth Factor? (VEGF)?

VEGF (vascular endotelial growth factor) is a vascular permeability factor. In other words, it’s a protein, which is produced by many cells which stimulate the formation of blood vessels.

 

VEGF is a sub family of growth factors.

 

What are the most common indications for Anti-VEGF injections?

In ophthalmology, we use anti-VEGF injections to treat a number of conditions, which include macular degeneration, diabetic macular oedema and anti-ocular illusions.

 

In other circumstances, we use anti-VEGF injections for the treatment of rubeosis or eye neovascularisation and macular oedema from other causes. Other conditions such as central serous chorioretinopathy occasionally will need treatment with anti VEGF injections.

 

Macular oedema after cataract surgery can occasionally benefit from anti-VEGF injections as well.

 

However, the main conditions are macular degeneration, diabetic macular oedema and ocular vein occlusion.

 

Where is the anti-VEGF agent injected?

These injections are administered into the vitreous cavity of the eye. It is the cavity behind the lens and in front of the retina. This is a large cavity of the eye which is full of vitreous gel. By injecting these substances into the vitreous cavity, it has access to the retina, where the disease is located.

 

How do various Anti-VEGF injections differ?

There are a number of anti-VEGF agents available which essentially differ in the size of the molecule, as well as in the number of growth factors they inhibit.

 

Broadly speaking, there have been a number of studies that have tried to compare one anti-VEGF agent to another. However, from a practical point of view, for the patient, what really matters is how effective the drug is and how long it works for. What the patient wants is to be able to have the disease controlled with the fewest injections possible.

 

Practically speaking, this is what we end up juggling in the practical sense in the clinic, in order for us to treat the patient and to maintain vision and macular leakage.

 

 

What can a patient expect after an Anti-VEGF injection?

At the time of the injection, we cleanse the eye before we start, which involves the use of Betadine, an iodine-based solution. This causes some degree of irritation to the eye.

 

Quite invariably, after the first 12-24 hours, the patient’s eyes are a little red and sore. In some cases, there will be more discomfort than others. In some cases, people may develop a degree of iodine or Betadine sensitivity, therefore the discomfort may last a bit longer than usual. However, usually after the first 24 hours, the discomfort will settle and the patient can resume normal activities.

 

The main warning that we give patients is that they should report any sudden onset of severe pain or loss of vision in the eye after the injection.

 

What are the possible complications of anti-VEGF treatments?

The most common side effects of anti-VEGF injections are ocular discomfort and ocular redness and irritation, which are often relieved by use of optical lubricants including any particular dose which are based on sodium hyaluronate. Patients have said that this is one of the bestlubricants to use to keep the eye comfortable after injections.

 

Other side effects include retinal attachment and retinal tears which fortunately are quite rare. Additionally, some patients may suffer from infection or endophthalmitis. This is a devastating complication of injections. It can lead to an infection inside the eye which can affect the vision dramatically in the long term if it did happen.

 

Finally, we need to bear in mind that there is a small risk of elevated ocular pressure after injections and ocular inflammation. Both can blur the vision and also cause ocular discomfort and therefore should be treated appropriately.  

 

 

 

If you would like to know more about anti-VEGF injections, do not hesitate to book a consultation with Mr Zambarakji, do not hesitate to do so by visiting his Top Doctors profile today.

By Mr Hadi Zambarakji
Ophthalmology

Mr Hadi Zambarakji is a highly-skilled consultant ophthalmic surgeon with a subspecialist interest in vitreoretinal and cataract surgery. He assists private patients at four highly regarded clinics across London and Essex. His private practice secretary is Miss Molly Mapp and he is assisted in clinic by Miss Rajinder Bharaj, Specialist Optometrist.

Mr. Zambarakji and his team are committed to providing a first class quality service and to ensuring that you are totally satisfied with the level of care they provide. With over 15 years' experience as a consultant, as well as a broad range of specialist skill, Mr Zambarakji provides a range of expertise in the fields of vitreoretinal and cataract surgery as well as medical retina. This includes but is not limited to, retinal detachment, macular holes, epiretinal membranes, vitreomacular traction, and advanced diabetic eye disease, as well as macular degeneration, retinal vein occlusion, and diabetic retinopathy.

Regarding cataract services, this includes premium lens implants (toric and multifocal/extended range) for greater independence from glasses. He was an early adopter of local anaesthesia for vitreoretinal surgery and performs most surgeries under local anaesthesia with sedation as day case.

Mr Zambarakji dedicates his career to patient care, but he also commits his time to medical research, which he has presented at national and international conferences. He has taken an active role in research throughout his training and continues to do so as a consultant. His research interests include imaging in retinal disorders, vitreomacular diseases and macular hole, diabetic macular oedema, investigational treatments for diabetic retinopathy and macular degeneration, complications of high myopia, and angiogenesis. A complete list of his research publications can be seen on PubMed.

He has taken up a number of additional roles including college tutor and regional advisor for The Royal College of Ophthalmologists, clinical governance lead for ophthalmology at Barts Heath, and examiner for the Royal College of Ophthalmologists. What's more, he is heavily involved in education and training and runs a busy vitreoretinal fellowship program at Whipps Cross University Hospital, Barts Health for future retina specialists.

You can view Mr Zambarakji's reviews on IWantGreatCare here.

View Profile

Overall assessment of their patients


  • Related procedures
  • Microdermoabrasion
    Microneedling
    Dark circles
    Mesotherapy
    Facelift
    Neck lift
    Botulinum toxin (Botox™)
    Dermal fillers
    Peeling
    Facial paralysis
    This website uses our own and third-party Cookies to compile information with the aim of improving our services, to show you advertising related to your preferences as well analysing your browsing habits. You can change your settings HERE.